A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Mivocabtagene autoleucel (Primary)
- Indications Dermatomyositis; Lupus nephritis; Multiple sclerosis; Myasthenia gravis; Rheumatoid arthritis; Stiff-person syndrome; Systemic scleroderma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms KYSA-4
Most Recent Events
- 16 Feb 2026 New trial record